Manidón (Verapamil Hydrochloride)

Verapamil blocks L-type calcium channels in cardiac and vascular smooth muscle. By reducing calcium entry, it relaxes blood vessels, decreases the force of heart muscle contraction, and slows electrical conduction through the atrioventricular node, leading to lower blood pressure and controlled heart rate.

The appropriate dose of Manidón is determined by the prescribing healthcare professional based on the individual’s medical condition, response to therapy, and other factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Verapamil should only be used during pregnancy or lactation if the potential benefit justifies the potential risk to the fetus or infant. Healthcare providers will evaluate the risk‑benefit profile before prescribing it to pregnant or nursing women.

To order Manidón, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Manidón (verapamil) belongs to the calcium channel blocker class, which reduces blood pressure by relaxing vascular smooth muscle. Compared with beta‑blockers or ACE inhibitors, verapamil also slows heart rate and AV‑node conduction, making it useful for patients who need both blood‑pressure control and heart‑rate reduction.

Manidón should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Manidón is taken orally, usually with a glass of water. It can be taken with or without food, but consistency with meals may help reduce gastrointestinal discomfort. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious risks include severe hypotension, marked bradycardia, and atrioventricular block, which can lead to fainting or cardiac complications. Patients should report symptoms such as dizziness, fainting, unusually slow heartbeat, or chest discomfort to their physician promptly.

Manidón is contraindicated in patients with known hypersensitivity to verapamil or other calcium channel blockers, those with severe sinus bradycardia, advanced atrioventricular block without a pacemaker, and in certain cases of acute myocardial infarction. A healthcare professional should evaluate suitability before prescribing.